title: Erlotinib-induced skin rash. Pathogenesis, clinical significance and management in pancreatic cancer patients.
abstract: Erlotinib is a tyrosine kinase inhibitor with anti epidermal growth factor receptor activity, approved as first line treatment concurrently administrated with gemcitabine for locally advanced unresectable or metastatic pancreatic cancer. One of the most common side effects, rash, is possibly linked to overall and progression-free survival and may serve as a potential surrogate marker. Nevertheless, erlotinib-induced rash is cause of negative impact on patients' quality of life and often can trigger discontinuation of treatment. Adequate and timely management of rash depending on the grade of rash is important for therapy continuation.
authors.affiliation: Section of Medical Oncology, Yale University School of Medicine, New Haven, CT 06520, USA. wasif.saif@yale.edu
authors.forename: Muhammad Wasif
authors.initials: MW
authors.lastname: Saif
authors.forename: Irene
authors.initials: I
authors.lastname: Merikas
authors.forename: Sotirios
authors.initials: S
authors.lastname: Tsimboukis
authors.forename: Kostas
authors.initials: K
authors.lastname: Syrigos
mesh_terms: D000465:Algorithms; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D000069347:Erlotinib Hydrochloride; D005076:Exanthema / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D018773:Genes, erbB-1; D006801:Humans; D015994:Incidence; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D020641:Polymorphism, Single Nucleotide; D011799:Quinazolines / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride